[go: up one dir, main page]

LT3080100T - Lizinui specifinės demetilazės-1 inhibitoriai - Google Patents

Lizinui specifinės demetilazės-1 inhibitoriai

Info

Publication number
LT3080100T
LT3080100T LTEPPCT/US2014/069562T LT14069562T LT3080100T LT 3080100 T LT3080100 T LT 3080100T LT 14069562 T LT14069562 T LT 14069562T LT 3080100 T LT3080100 T LT 3080100T
Authority
LT
Lithuania
Prior art keywords
lysine
inhibitors
specific demethylase
demethylase
specific
Prior art date
Application number
LTEPPCT/US2014/069562T
Other languages
English (en)
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of LT3080100T publication Critical patent/LT3080100T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/US2014/069562T 2013-12-11 2014-12-10 Lizinui specifinės demetilazės-1 inhibitoriai LT3080100T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914927P 2013-12-11 2013-12-11
PCT/US2014/069562 WO2015089192A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
LT3080100T true LT3080100T (lt) 2023-02-27

Family

ID=53371806

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/069562T LT3080100T (lt) 2013-12-11 2014-12-10 Lizinui specifinės demetilazės-1 inhibitoriai

Country Status (17)

Country Link
US (3) US9944636B2 (lt)
EP (2) EP4257591A3 (lt)
JP (1) JP6430512B2 (lt)
CA (2) CA2933480C (lt)
DK (1) DK3080100T3 (lt)
ES (1) ES2935746T3 (lt)
FI (1) FI3080100T3 (lt)
HR (1) HRP20230086T1 (lt)
HU (1) HUE061252T2 (lt)
LT (1) LT3080100T (lt)
MX (2) MX2016007585A (lt)
PL (1) PL3080100T3 (lt)
PT (1) PT3080100T (lt)
RS (1) RS63939B1 (lt)
SI (1) SI3080100T1 (lt)
SM (1) SMT202300014T1 (lt)
WO (1) WO2015089192A1 (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CN111454188A (zh) 2014-02-13 2020-07-28 因赛特公司 作为lsd1抑制剂的环丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EA201691594A1 (ru) 2014-02-13 2017-02-28 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
EP3137169B1 (en) * 2014-05-01 2021-11-10 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
JP6587241B2 (ja) 2014-06-27 2019-10-09 セルジーン クオンティセル リサーチ，インク． リジン特異的なデメチラーゼ−１の阻害剤
EP3164380B1 (en) * 2014-07-03 2022-02-09 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX2017002824A (es) * 2014-09-05 2017-05-30 Celgene Quanticel Res Inc Inhibidores demetilasa-1 especifica de lisina.
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
CN107849611A (zh) 2015-06-12 2018-03-27 奥瑞泽恩基因组学股份有限公司 与lsd1抑制剂相关的生物标志物及其用途
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3334709B1 (en) 2015-08-12 2024-12-11 Incyte Holdings Corporation Salts of an lsd1 inhibitor
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
CA3006434C (en) * 2015-11-27 2021-03-16 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
CA3009805C (en) 2015-12-29 2023-10-17 Mirati Therapeutics, Inc. Lsd1 inhibitors
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
CN105924397B (zh) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018213211A1 (en) * 2017-05-15 2018-11-22 The Regents Of The University Of Michigan Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
MX2019014104A (es) 2017-05-26 2020-02-07 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
HUE062769T2 (hu) * 2017-05-26 2023-12-28 Taiho Pharmaceutical Co Ltd Antitumor potenciátor bifenil vegyület felhasználásával
TWI749235B (zh) 2017-05-31 2021-12-11 日商大鵬藥品工業股份有限公司 基於insm1表現之lsd1抑制劑之治療效果的預測方法
EP3661510B1 (en) 2017-08-03 2024-10-09 Oryzon Genomics, S.A. Methods of treating behavior alterations
TWI794294B (zh) 2017-09-13 2023-03-01 南韓商韓美藥品股份有限公司 吡唑衍生化合物及其用途
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
PH12021552251A1 (en) 2019-03-20 2022-07-25 Oryzon Genomics Sa Methods of treating borderline personality disorder
MX2021011254A (es) 2019-03-20 2021-10-01 Oryzon Genomics Sa Metodos de tratamiento del trastorno por deficit de atencion e hiperactividad.
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
EP1397142A4 (en) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
KR20050013534A (ko) * 2002-03-28 2005-02-04 에자이 가부시키가이샤 ｃ─Ｊｕｎ Ｎ─말단 키나아제 억제용 아자인돌
AU2003295776B2 (en) 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2007006581A2 (en) 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
CA2640398A1 (en) * 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
BRPI0808888B8 (pt) * 2007-03-12 2021-05-25 Cytopia Res Pty Ltd composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
AU2009275957A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
EP2258865A1 (en) * 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
US9708255B2 (en) * 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011143057A1 (en) * 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9006449B2 (en) * 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
GB201106829D0 (en) * 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2013033688A1 (en) 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
AR088351A1 (es) * 2011-10-31 2014-05-28 Lilly Co Eli Analogos de pirazol sustituidos
ME03573B (me) * 2012-05-04 2020-07-20 Samumed Llc 1H-PIRAZOLO[3,4-B]PIRIDINI l NJIHOVA TERAPEUTSKA UPOTREBA
WO2013175789A1 (ja) 2012-05-24 2013-11-28 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子

Also Published As

Publication number Publication date
FI3080100T3 (fi) 2023-03-15
JP2017502940A (ja) 2017-01-26
EP3080100A1 (en) 2016-10-19
EP3080100A4 (en) 2017-09-06
SMT202300014T1 (it) 2023-05-12
SI3080100T1 (sl) 2023-04-28
JP6430512B2 (ja) 2018-11-28
HUE061252T2 (hu) 2023-05-28
US10385051B2 (en) 2019-08-20
DK3080100T3 (da) 2023-02-06
EP4257591A2 (en) 2023-10-11
PT3080100T (pt) 2023-01-19
EP4257591A3 (en) 2023-11-22
HRP20230086T1 (hr) 2023-03-31
US20160304516A1 (en) 2016-10-20
ES2935746T3 (es) 2023-03-09
US20190055242A1 (en) 2019-02-21
US20180179204A1 (en) 2018-06-28
PL3080100T3 (pl) 2023-03-06
MX2020010496A (es) 2020-10-28
US10131664B2 (en) 2018-11-20
EP3080100B1 (en) 2022-11-30
CA2933480A1 (en) 2015-06-18
CA2933480C (en) 2022-08-23
WO2015089192A1 (en) 2015-06-18
US9944636B2 (en) 2018-04-17
CA3161836A1 (en) 2015-06-18
MX2016007585A (es) 2016-12-16
RS63939B1 (sr) 2023-02-28

Similar Documents

Publication Publication Date Title
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
EP2948458A4 (en) BTK INHIBITORS
EP2948431A4 (en) BTK INHIBITORS
DK3077047T3 (da) Aramcholsalte
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
EP2952513A4 (en) AZOLE AND BENZENE DERIVATIVE
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
EP2969096A4 (en) Bottle pressurization delivery system
DK3068314T3 (da) Årepresse
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2970310A4 (en) 5-BROMO-indirubins
DE102013106534B8 (de) Chromatographiepipettenspitze
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK2981168T3 (da) Laminitiskile
DK3086679T3 (da) Sportssko